Search Results - "Boucher, Charles Ab"

Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity by van Maarseveen, Noortje M, Andersson, Dan, Lepšík, Martin, Fun, Axel, Schipper, Pauline J, de Jong, Dorien, Boucher, Charles A B, Nijhuis, Monique

“…Mutations in the substrate of HIV-1 protease, especially changes in the NC/p1 cleavage site, can directly contribute to protease inhibitor (PI) resistance and…”
Get full text

Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study by Vliet, Marjolein M, Hendrickson, Cheryl, Nichols, Brooke E, Boucher, Charles AB, Peters, Remco PH, Vijver, David AMC

“…Introduction Although pre‐exposure prophylaxis (PrEP.) is an efficacious HIV prevention strategy, its preventive benefit has not been shown among young women…”
Get full text

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype by Sonneveld, Milan J, Rijckborst, Vincent, Cakaloglu, Yilmaz, Simon, Krzysztof, Heathcote, E Jenny, Tabak, Fehmi, Mach, Tomasz, Boucher, Charles A B, Hansen, Bettina E, Zeuzem, Stefan, Janssen, Harry L A

“…On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e…”
Get more information

Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands by Schreuder, Imke, van der Sande, Marianne Ab, de Wit, Matty, Bongaerts, Monique, Boucher, Charles Ab, Croes, Esther A, van Veen, Maaike G

“…Injecting drug users (IDU) remain an important population at risk for blood-borne infections such as human immunodeficiency virus (HIV), hepatitis B virus…”
Get full text

Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase by Huigen, Marleen C D G, van Ham, Petronella M, de Graaf, Loek, Kagan, Ron M, Boucher, Charles A B, Nijhuis, Monique

“…HIV-1 nucleoside reverse transcriptase inhibitors (NRTIs) have been used in the clinic for over twenty years. Interestingly, the complete resistance pattern to…”
Get full text

Increasing the use of second‐line therapy is a cost‐effective approach to prevent the spread of drug‐resistant HIV: a mathematical modelling study by Nichols, Brooke E, Sigaloff, Kim CE, Kityo, Cissy, Hamers, Raph L, Baltussen, Rob, Bertagnolio, Silvia, Jordan, Michael R, Hallett, Timothy B, Boucher, Charles AB, Wit, Tobias F Rinke, Vijver, David AMC

“…Introduction Earlier antiretroviral therapy (ART) initiation reduces HIV‐1 incidence. This benefit may be offset by increased transmitted drug resistance…”
Get full text

Emergence of a Multidrug-Resistant Pandemic Influenza A (H1N1) Virus by van der Vries, Erhard, Stelma, Foekje F, Boucher, Charles A.B

“…To the Editor: Since the outbreak of influenza A (H1N1) virus pandemic, almost 300 cases of infection with an oseltamivir-resistant influenza virus have been…”
Get full text

Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline by Sonneveld, Milan J., Rijckborst, Vincent, Boucher, Charles A. B., Hansen, Bettina E., Janssen, Harry L. A.

“…Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG‐IFN). We investigated within a large…”
Get full text

Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels by Rijckborst, Vincent, Hansen, Bettina E., Cakaloglu, Yilmaz, Ferenci, Peter, Tabak, Fehmi, Akdogan, Meral, Simon, Krzysztof, Akarca, Ulus S., Flisiak, Robert, Verhey, Elke, Van Vuuren, Anneke J., Boucher, Charles A. B., ter Borg, Martijn J., Janssen, Harry L. A.

“…Peginterferon alfa‐2a results in a sustained response (SR) in a minority of patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B (CHB)…”
Get full text

HIV monotherapy with ritonavir-boosted protease inhibitors : a systematic review by BIERMAN, Wouter F. W, VAN AGTMAEL, Michiel A, NIJHUIS, Monique, DANNER, Sven A, BOUCHER, Charles A. B

“…To assess the efficacy of ritonavir-boosted protease inhibitor monotherapy. Systematic review of all protease inhibitor-monotherapy studies published in…”
Get full text

Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients by Rokx, Casper, Schurink, Carolina A M, Boucher, Charles A B, Rijnders, Bart J A

“…Dolutegravir is recommended as part of combination ART (cART) for HIV-1-infected patients. Toxicities, drug interactions and costs related to cART still…”
Get full text

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics by Abecasis, Ana B, Wensing, Annemarie M J, Paraskevis, Dimitris, Vercauteren, Jurgen, Theys, Kristof, Van de Vijver, David A M C, Albert, Jan, Asjö, Birgitta, Balotta, Claudia, Beshkov, Danail, Camacho, Ricardo J, Clotet, Bonaventura, De Gascun, Cillian, Griskevicius, Algis, Grossman, Zehava, Hamouda, Osamah, Horban, Andrzej, Kolupajeva, Tatjana, Korn, Klaus, Kostrikis, Leon G, Kücherer, Claudia, Liitsola, Kirsi, Linka, Marek, Nielsen, Claus, Otelea, Dan, Paredes, Roger, Poljak, Mario, Puchhammer-Stöckl, Elisabeth, Schmit, Jean-Claude, Sönnerborg, Anders, Stanekova, Danika, Stanojevic, Maja, Struck, Daniel, Boucher, Charles A B, Vandamme, Anne-Mieke

“…Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug…”
Get full text

H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis by van der Vries, Erhard, Collins, Patrick J, Vachieri, Sebastien G, Xiong, Xiaoli, Liu, Junfeng, Walker, Philip A, Haire, Lesley F, Hay, Alan J, Schutten, Martin, Osterhaus, Albert D M E, Martin, Steve R, Boucher, Charles A B, Skehel, John J, Gamblin, Steve J

“…Two classes of antiviral drugs, neuraminidase inhibitors and adamantanes, are approved for prophylaxis and therapy against influenza virus infections. A major…”
Get full text

Transmission networks of HIV-1 among men having sex with men in the Netherlands by BEZEMER, Daniela, VAN SIGHEM, Ard, DE WOLF, Frank, LUKASHOV, Vladimir V, VAN DER HOEK, Lia, BACK, Nicole, SCHUURMAN, Rob, BOUCHER, Charles A. B, CLAAS, Eric C. J, BOERLIJST, Maarten C, COUTINHO, Roel A

“…To obtain insight in the HIV-1 transmission networks among men having sex with men (MSM) in the Netherlands. A phylogenetic tree was constructed from…”
Get full text

Evolutionary pathways of transmitted drug-resistant HIV-1 by Pingen, Marieke, Nijhuis, Monique, de Bruijn, Johan A., Boucher, Charles A. B., Wensing, Annemarie M. J.

“…Several large studies in Europe and the USA revealed that approximately 10% of all newly diagnosed patients harbour HIV-1 variants with at least one major…”
Get full text

Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir by BAXTER, John D, SCHAPIRO, Jonathan M, BOUCHER, Charles A. B, KOHLBRENNER, Veronika M, HALL, David B, SCHERER, Joseph R, MAYERS, Douglas L

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism by Nijhuis, Monique, van Maarseveen, Noortje M, Lastere, Stephane, Schipper, Pauline, Coakley, Eoin, Glass, Bärbel, Rovenska, Mirka, de Jong, Dorien, Chappey, Colombe, Goedegebuure, Irma W, Heilek-Snyder, Gabrielle, Dulude, Dominic, Cammack, Nick, Brakier-Gingras, Lea, Konvalinka, Jan, Parkin, Neil, Kräusslich, Hans-Georg, Brun-Vezinet, Francoise, Boucher, Charles A B

“…HIV protease inhibitor (PI) therapy results in the rapid selection of drug resistant viral variants harbouring one or two substitutions in the viral protease…”
Get full text

A Summary of the First HIV Microbiome Workshop 2015 by Williams, Brett, Mirmonsef, Paria, Boucher, Charles A B, Bushman, Frederic, Carrington-Lawrence, Stacy, Collman, Ronald G, Dandekar, Satya, Dang, Que, Malaspina, Angela, Paredes, Roger, Stone, Arthur, Landay, Alan

“…The role of microbiota in the pathogenesis of HIV infection has become the subject of intense research in recent years. A rapidly growing amount of data…”
Get more information

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B by Sonneveld, Milan J, Rijckborst, Vincent, Boucher, Charles A.B, Zwang, Louwerens, Beersma, Matthias F.C, Hansen, Bettina E, Janssen, Harry L.A

“…Abstract Background and objectives Serum Hepatitis B surface Antigen (HBsAg) levels correlate with hepatitis B virus intrahepatic covalently closed circular…”
Get full text

Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study by NICHOLS, Brooke E, SIGALOFF, Kim C. E, KITYO, Cissy, MANDALIYA, Kishor, HAMERS, Raph L, BERTAGNOLIO, Silvia, JORDAN, Michael R, BOUCHER, Charles A. B, RINKE DE WIT, Tobias F, VAN DE VIJVER, David A. M. C

“…Earlier antiretroviral therapy initiation can reduce the incidence of HIV-1. This benefit can be offset by increased transmitted drug resistance (TDR). We…”
Get full text